OBJECTIVE: The study objective was to compare the incidence and prognosis of acute myocardial infarction when using high-sensitivity cardiac troponin assays instead of a standard cardiac troponin assay for the diagnosis of acute myocardial infarction. METHODS: In a prospective international multicenter study, we enrolled 1124 consecutive patients presenting with suspected acute myocardial infarction. Final diagnoses were adjudicated by 2 independent cardiologists 2 times using all available clinical information: first using standard cardiac troponin levels and second using high-sensitivity cardiac troponin T levels for adjudication. Patients were followed up for a mean of 19±9 months. RESULTS: The use of high-sensitivity cardiac troponin T instead of standard cardiac troponin resulted in an increase in the incidence of acute myocardial infarction from 18% to 22% (242 vs 198 patients), a relative increase of 22%. Of the 44 additional acute myocardial infarctions, 35 were type 1 acute myocardial infarctions and 9 were type 2 acute myocardial infarctions. This was accompanied by a reciprocal decrease in the incidence of unstable angina (unstable angina, 11% vs 13%). The most pronounced increase was observed in patients adjudicated with cardiac symptoms of origin other than coronary artery disease with cardiomyocyte damage (83 vs 31 patients, relative increase of 268%). Cumulative 30-month mortality rates were 4.8% in patients without acute myocardial infarction, 16.4% in patients with a small acute myocardial infarction detected only by high-sensitivity cardiac troponin T but not standard cardiac troponin, and 23.9% in patients with a moderate/large acute myocardial infarction according to standard cardiac troponin assays and high-sensitivity cardiac troponin T (P<.001). CONCLUSIONS: The introduction of high-sensitivity cardiac troponin assays leads to only a modest increase in the incidence of acute myocardial infarction. The novel sensitive assays identify an additional high-risk group of patients with increased mortality, therefore appropriately classified with acute myocardial infarction (Advantageous Predictors of Acute Coronary Syndromes Evaluation; NCT00470587).
OBJECTIVE: The study objective was to compare the incidence and prognosis of acute myocardial infarction when using high-sensitivity cardiac troponin assays instead of a standard cardiac troponin assay for the diagnosis of acute myocardial infarction. METHODS: In a prospective international multicenter study, we enrolled 1124 consecutive patients presenting with suspected acute myocardial infarction. Final diagnoses were adjudicated by 2 independent cardiologists 2 times using all available clinical information: first using standard cardiac troponin levels and second using high-sensitivity cardiac troponin T levels for adjudication. Patients were followed up for a mean of 19±9 months. RESULTS: The use of high-sensitivity cardiac troponin T instead of standard cardiac troponin resulted in an increase in the incidence of acute myocardial infarction from 18% to 22% (242 vs 198 patients), a relative increase of 22%. Of the 44 additional acute myocardial infarctions, 35 were type 1 acute myocardial infarctions and 9 were type 2 acute myocardial infarctions. This was accompanied by a reciprocal decrease in the incidence of unstable angina (unstable angina, 11% vs 13%). The most pronounced increase was observed in patients adjudicated with cardiac symptoms of origin other than coronary artery disease with cardiomyocyte damage (83 vs 31 patients, relative increase of 268%). Cumulative 30-month mortality rates were 4.8% in patients without acute myocardial infarction, 16.4% in patients with a small acute myocardial infarction detected only by high-sensitivity cardiac troponin T but not standard cardiac troponin, and 23.9% in patients with a moderate/large acute myocardial infarction according to standard cardiac troponin assays and high-sensitivity cardiac troponin T (P<.001). CONCLUSIONS: The introduction of high-sensitivity cardiac troponin assays leads to only a modest increase in the incidence of acute myocardial infarction. The novel sensitive assays identify an additional high-risk group of patients with increased mortality, therefore appropriately classified with acute myocardial infarction (Advantageous Predictors of Acute Coronary Syndromes Evaluation; NCT00470587).
Authors: Xiao-Dong Ye; Yi He; Sheng Wang; Gordon T Wong; Michael G Irwin; Zhengyuan Xia Journal: Acta Pharmacol Sin Date: 2018-05-17 Impact factor: 6.150
Authors: Claire E Raphael; Véronique L Roger; Yader Sandoval; Mandeep Singh; Malcolm Bell; Amir Lerman; Charanjit S Rihal; Bernard J Gersh; Bradley Lewis; Ryan J Lennon; Allan S Jaffe; Rajiv Gulati Journal: Circulation Date: 2020-01-06 Impact factor: 29.690
Authors: Flavia Ballocca; Fabrizio D'Ascenzo; Claudio Moretti; Roberto Diletti; Carlo Budano; Alberto Palazzuoli; Matthew J Reed; Tullio Palmerini; Dariusz Dudek; Alfredo Galassi; Pierluigi Omedè; Nicolas M Mieghem; David Ferenbach; Marco Pavani; Diego Della Riva; Nick L Mills; Ron T Van Domburgh; Andrea Mariani; Artur Dziewierz; Marco di Cuia; Robert Jan van Geuns; Felix Zijlstra; Serena Bergerone; Sebastiano Marra; Giuseppe Biondi Zoccai; Fiorenzo Gaita Journal: Cardiol J Date: 2017-03-10 Impact factor: 2.737
Authors: Min Chul Kim; Seok Oh; Youngkeun Ahn; Keumyi Moon; Joon Ho Ahn; Dae Young Hyun; Kyung Hoon Cho; Doo Sun Sim; Young Joon Hong; Ju Han Kim; Myung Ho Jeong; Jeong Gwan Cho; Jong Chun Park Journal: Korean J Intern Med Date: 2021-01-04 Impact factor: 2.884